logo

Asia-Pacific Oral Anti-Diabetic Drug Market Size (2024 - 2029)

The Asia-Pacific Oral Anti-Diabetic Drug Market is projected to experience growth over the forecast period, driven by an increasing prevalence of diabetes, particularly type 2, and an aging population in the region. The demand for advanced diabetes medications has risen, partly due to the impact of COVID-19 on patients with pre-existing conditions. Factors such as sedentary lifestyles, stress, and unhealthy habits contribute to the growing diabetes rates, while the local production infrastructure supports market expansion. Despite these growth drivers, the rising cost of pharmaceuticals poses a significant challenge to the market's development.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Diabetes Care Drugs Research Asia-Pacific Oral Anti-Diabetic Drug Market Market Size

Market Size of Asia-Pacific Oral Anti-Diabetic Drug Industry

Asia-Pacific Oral Anti-Diabetic Drug Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 25.37 Billion
Market Size (2029) USD 29.56 Billion
CAGR (2024 - 2029) 3.10 %

Major Players

Asia-Pacific Oral Anti-Diabetic Drug Market Major Players

*Disclaimer: Major Players sorted in no particular order

Asia-Pacific Oral Anti-Diabetic Drug Market Analysis

The Asia-Pacific Oral Anti-Diabetic Drug Market size is estimated at USD 24.61 billion in 2023, and is expected to reach USD 28.67 billion by 2028, growing at a CAGR of 3.10% during the forecast period (2023-2028).

The Asia-Pacific market for oral anti-diabetic drugs is poised for substantial growth, driven by an aging demographic and escalating diabetes rates. Factors such as heightened stress, sedentary lifestyles, smoking, and excessive alcohol consumption are primary contributors to the rising prevalence of diabetes, leading to elevated blood sugar levels.

The region's escalating diabetes rates are a key driver for the growing demand for oral anti-diabetic medications. For instance, projections from IDF indicate that the number of individuals with diabetes in Southeast Asia is set to surge by 68%, reaching around 152 million by 2045. Additionally, the diabetes prevalence rate is expected to surge by 30%, reaching 11.3% in 2045. Moreover, health-related expenditures for diabetes are expected to rise from USD 17,675.4 million in 2030 to USD 21,200.0 million in 2045. This surge in health-related spending, coupled with the climbing diabetes prevalence, is set to underpin the market's expansion.

Advancements in drug delivery technologies, particularly in oral formats, are poised to propel market growth further. For instance, in May 2024, an international team led by Australian researchers introduced a nanotechnology-based system. This innovation paves the way for a future where individuals with diabetes could potentially consume oral insulin. The researchers highlight that this new form of insulin could be ingested via a tablet or even concealed within a piece of chocolate, offering a more palatable option, especially for elderly diabetic patients averse to injections.

The Asia-Pacific oral anti-diabetic drug market is progressing significantly. The rising prevalence of diabetes and advancements in drug delivery technologies will continue to drive demand and innovation. The market is expected to benefit from rising health-related expenditures and the development of more accessible and user-friendly medication formats.

Asia-Pacific Oral Anti-Diabetic Drug Industry Segmentation

The Asia-Pacific oral anti-diabetic drug market is segmented into drugs and geography. By drugs, the market is segmented into biguanides, alpha-glucosidase inhibitors, dopamine-d2 receptor agonists, sodium-glucose cotransport-2 (SGLT-2) inhibitor, dipeptidyl peptidase-4 (DPP-4) inhibitors, sulfonylureas, and meglitinides. By geography, the market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia-Pacific. The report offers the value (USD) for all the above segments.

By Drugs Type
Biguanides
Alpha-Glucosidase Inhibitors
Dopamine D2 Receptor Agonist
SGLT-2 Inhibitors
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Others
DPP-4 inhibitors
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina(Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Meglitinides
By Patient Type
Adult
Geriatic
Pediatric
Geography
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Need A Different Region Or Segment?
Customize Now

Asia-Pacific Oral Anti-Diabetic Drug Market Size Summary

The Asia-Pacific oral anti-diabetic drug market is poised for growth, driven by an increasing prevalence of diabetes, particularly type 2, in the region. This rise is attributed to factors such as an aging population, sedentary lifestyles, and lifestyle choices like smoking and excessive alcohol consumption. The market is characterized by the dominance of metformin, a widely prescribed biguanide-class medication, due to its favorable risk/benefit ratio and cost-effectiveness. The region's market expansion is further supported by advancements in production infrastructure and the introduction of innovative diabetes medications. However, the rising cost of pharmaceuticals presents a significant challenge to market growth.

China and Japan are identified as key markets within the Asia-Pacific region, with China holding a substantial share of the global diabetes medicine market. The presence of numerous generic medication manufacturers in China and the well-organized medical insurance systems in Japan contribute to the market's robustness. Despite Japan's mature market status, it faces challenges such as economic stagnation and an aging population. Leading pharmaceutical companies like Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals are focusing on innovation to capture market share. Recent developments, such as Oramed's oral insulin capsule and Eurofarma's Suganon, highlight the ongoing efforts to enhance diabetes treatment options in the region.

Explore More

Asia-Pacific Oral Anti-Diabetic Drug Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Government Support Initiatives to Construct the Spread of Diabetes

      2. 1.2.2 Rising Prevalence of Diabetes

    3. 1.3 Market Restraints

      1. 1.3.1 Stringent Regulatory Requirements in the Industry

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size By Value - USD)

    1. 2.1 By Drugs Type

      1. 2.1.1 Biguanides

      2. 2.1.2 Alpha-Glucosidase Inhibitors

      3. 2.1.3 Dopamine D2 Receptor Agonist

      4. 2.1.4 SGLT-2 Inhibitors

        1. 2.1.4.1 Invokana (Canagliflozin)

        2. 2.1.4.2 Jardiance (Empagliflozin)

        3. 2.1.4.3 Farxiga/Forxiga (Dapagliflozin)

        4. 2.1.4.4 Others

      5. 2.1.5 DPP-4 inhibitors

        1. 2.1.5.1 Onglyza (Saxagliptin)

        2. 2.1.5.2 Tradjenta (Linagliptin)

        3. 2.1.5.3 Vipidia/Nesina(Alogliptin)

        4. 2.1.5.4 Galvus (Vildagliptin)

      6. 2.1.6 Sulfonylureas

      7. 2.1.7 Meglitinides

    2. 2.2 By Patient Type

      1. 2.2.1 Adult

      2. 2.2.2 Geriatic

      3. 2.2.3 Pediatric

    3. 2.3 Geography

      1. 2.3.1 China

      2. 2.3.2 Japan

      3. 2.3.3 India

      4. 2.3.4 Australia

      5. 2.3.5 South Korea

      6. 2.3.6 Rest of Asia-Pacific

Asia-Pacific Oral Anti-Diabetic Drug Market Size FAQs

The Asia-Pacific Oral Anti-Diabetic Drug Market size is expected to reach USD 25.37 billion in 2024 and grow at a CAGR of 3.10% to reach USD 29.56 billion by 2029.

In 2024, the Asia-Pacific Oral Anti-Diabetic Drug Market size is expected to reach USD 25.37 billion.

Asia-Pacific Oral Anti-Diabetic Drug Market Report Snapshots

Asia-Pacific Oral Anti-Diabetic Drug Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)